Published Date:2021-06-03
Original Link:https://www.onenessbio.com/en/news_detail45_3.htm
| No | 1 | Date of announcement | 2021/06/03 | Time of announcement | 18:48:46 |
|---|---|---|---|---|---|
| Subject | The Phase 3 international MRCT study results of the diabetic foot ulcer new drug, Fespixon have been accepted for oral presentation at the 57th EASD Annual Meeting | ||||
| To which item it meets |
paragraph 12 | Date of events | 2021/06/03 | ||
| Statement | |||||
|
1.Date of institutional investor conference:2021/09/30 2.Time of institutional investor conference:19:30 (TPE time) 3.Location of institutional investor conference: EASD Virtual Annual Meeting 4.Outline of institutional investor conference: (1)The Phase 3 international MRCT results of Fespixon,new drug for diabetic foot ulcers, have been accepted for an oral presentation at the 57th European Association for the Study of Diabetes (EASD) Annual Meeting at 19:30–21:00 on 30th of September 2021 (local time CEST 13:30–15:00). The annual meeting of this year will be held virtually due to the global pandemic of COVID-19. (2)The European Association for the Study of Diabetes (EASD) has been established since 1965. The EASD Annual Meeting has been one of the largest and most reputable scientific congress on diabetes in Europe.The congress covers diabetes-related researches and focuses in the important progress of fundamental science, prevention, diagnosis and treatments in diabetes. Over 15,000 scientists or healthcare professionals from more than 130 countries participated in the congress each year. 5.Any other matters that need to be specified:The presentation slides will be made publicly by being uploaded to Market Observation Post System according to the regulation. |
|||||